Products new and old take Pfizer past $6bn threshold in Japan
This article was originally published in Scrip
Executive Summary
Growth for most mainstay products, new launches, the June 2010 local merger with Wyeth and entry into the branded generics sector all combined to propel Pfizer to the top spot in Japan's prescription market last year, at least by some measures.